Global Life Science Business Partnering (GLSBP) - November 2024

Highlights of Deals in November 2024

 

1.     RED.Health inks pact with Boehringer India arm to improve its stroke care services.

2.     Intas Pharmaceuticals and Xbrane Biopharma have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

3.     360 ONE Asset acquires stake in OneSource Specialty Pharma.

4.     Aurobindo joins hands with global pharma player to develop respiratory products.

5.     SunAct Partners with Abgentil to Introduce CAR-T, TCR, and TIL therapies in India.

6.     AbbVie banks on Alzheimer's therapy with US$1.4 Billion buy of Aliada.

7.     Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in US$300 Million licensing deal.

8.     Novartis to pay Monte Rosa US$150 Million upfront to develop a new class of drugs.

9.     Cytokinetics, Bayer ink pact to develop HCM investigational drug Aficamten in Japan.

10.  Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle.

11.  Molbio Diagnostics has announced a $30 million investment in San Jose, US-based OptraSCAN.

12.  GE HealthCare inks partnership with RadNet in mammography AI.

13.  NEOGAP Therapeutics partners with NorthX Biologics.

14.  Roche to acquire US firm Poseida Therapeutics.

 

Aagami Updates:

1.     Aagami received contract expansion and extension from a US client to support them in JV/Acquisition/Investment initiatives.

2.     Aagami VP Godwyn Francis completed a very fruitful BIO-Europe 2024 conference in Stockholm, Sweden with over 35 startegic meetings with key decision makers.

3.     Aagami CEO Dinesh Jain to attend JPM week 2025 and Biotech Showcase in San Francisco from January 13-17, 2025.

4.     The Biotech Showcase 2025 (Jan 12-15) partnering system is now open. Please send us your meeting requests soon.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. Also, Phase 2 trials are starting in Central Africa for MPOX.

2.     Licensing: Several Biosimilars available for Partnering in Japan

a.     Denosumab (Prolia® & Xgeva®)

b.     Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

c.     Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]

d.     Liraglutide (Victoza®) [ For Diabetes ]

e.     Tocilizumab (Actemra®) [ For Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), Active Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) and patients with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation. ]

3.     Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU].

  1. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

2.     US IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

3.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

  1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
  2. Seeking Investments/Partnerships: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity.
  3. Engineering Therapeutics to Block Pathogenic Autoantibodies: Currently Need $4M seed to:
    1. Define clear FDA regulatory path
    2. Complete formulation of lead decoy; GLP studies in vitro
    3. Prepare for $7-$10M Series A raise for First in Human trials

Specialized Services

1.     Oligonucleotide and peptides specialist CDMO for one stop solution to accelerate R&D.

2.     In vivo pharmacology specialists (Mirimus) - Your new partner in Drug Discovery.


Hope you found the content useful. We welcome your feedback and queries.

×
Twitter